ACS Nano 12 (11), 1135511365
Overall, modulating the drivers of oxidative stress and cellular dysfunction offers a promising avenue for halting or reversing the progression of NAFLD
Introduction 1
In: Schwarz MI, King TE Jr, eds
Tirzepatide is a dual GIP/GLP-1 receptor agonist that produces mean body weight reductions of 20.9% at 72 weeks by delaying gastric emptying, suppressing ghrelin rebound, and enhancing glucose-dependent insulin secretion
Moreover, supplementation with Lactobacillus plantarum (DP189) and GOS restored gut microbial composition, improved gut and BBB integrity, reduced cortical inflammation and elevated acetylcholinesterase activity, reversing anxiety and depression-like behaviors in mice (Wang J